Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer

INTRODUCTION: Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer (mCRPC). Access to these medications varies significantly worldwide. In Australia until recently, patients must have received docetaxel first, unless unsuitable for chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Anton, Angelyn, Pillai, Sruti, Semira, Marie Christine, Wong, Shirley, Shapiro, Julia, Weickhardt, Andrew, Azad, Arun, Kwan, Edmond M., Spain, Lavinia, Gunjur, Ashray, Torres, Javier, Parente, Phillip, Parnis, Francis, Goh, Jeffrey, Baenziger, Olivia, Gibbs, Peter, Tran, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045563/
https://www.ncbi.nlm.nih.gov/pubmed/35492221
http://dx.doi.org/10.1002/bco2.129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045563/
https://www.ncbi.nlm.nih.gov/pubmed/35492221
http://dx.doi.org/10.1002/bco2.129

Ejemplares similares